Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 14/20 | 1.00 |
| ▸ | CDK9 | P50750 | 7/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.65 |
| ▸ | CDC7 | O00311 | 5/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 5/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 5/20 | 0.65 |
| ▸ | PIM1 | P11309 | 5/20 | 0.65 |
| ▸ | PRKACA | P17612 | 5/20 | 0.65 |
| ▸ | CLK2 | P49760 | 5/20 | 0.65 |
| ▸ | GSK3B | P49841 | 5/20 | 0.65 |
| ▸ | CDK7 | P50613 | 5/20 | 0.65 |
| ▸ | PRKX | P51817 | 5/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.65 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.65 |
| ▸ | PAK4 | O96013 | 4/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 4/20 | 0.65 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.65 |
| ▸ | CDK8 | P49336 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1604145 | 0.96 | PDPK1 (1.00) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1603855 | 0.89 | PDPK1 (0.81) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1604041 | 0.89 | PDPK1 (1.00) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1603905 | 0.89 | PDPK1 (0.80) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1457158 | 0.88 | PDPK1 (0.81) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1604049 | 0.88 | PDPK1 (1.00) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1604217 | 0.87 | PDPK1 (1.00) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL12707194 | 0.86 | PDPK1 (0.78) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1604736 | 0.85 | PDPK1 (0.74) | PDPK1CDK9CDK5CDC7DAPK3 | |
| SCHEMBL1603523 | 0.85 | PDPK1 (1.00) | PDPK1CDK9CDK5CDC7DAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| WO-2008155000-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MKI67, TYMP, TK2 | PDPK1 386/4885CDK9 30/4885CDK5 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.